Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONDYVAC: HPV Vaccine to Prevent Recurrence of External Genital Warts
2024-516098-62-00Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Dec 2024
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of recombinant human papillomavirus 9-valent vaccine and qHPV vaccine in anogenital warts and human papillomavirus infection (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Relapse-free survival. Started Dec 2024; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccineqHPV vaccine
03
Conditions
anogenital wartshuman papillomavirus infection
Beyond the preview
Go deeper on 2024-516098-62-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516098-62-00.